An Update on Scientific Advances and Clinical Strategies in Migraine

The 59th Annual Scientific Meeting of the American Headache Society (AHS) was held in Boston, Massachusetts, June 8 to June 11, 2017. The conference attracts medical professionals involved in the care of patients with head, neck, and orofacial pain. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on migraine.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with migraine.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Discuss recent advances in acute treatment of migraine
  2. Evaluate recent clinical data with CGRP system blocking mAbs for the preventive treatment of episodic and chronic migraine

FACULTY

Grace Forde, MD
Director
Neurological Services
North American Partners in Pain Management, LLP
North Shore University Hospital
Syosset, New York
Valley Stream, New York

Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
Director
Dartmouth Headache Center
Department of Neurology
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterRelationship Identified With:

Grace Forde, MD

Speakers’ Bureau: Allergan; PERNIX Therapeutics

Stewart J. Tepper, MD

Consultant/Advisor: Acorda Therapeutics; Alder BioPharmaceuticals Inc.; Allergan Inc.; Amgen Inc; Autonomic Technologies Inc.; BioVision Inc; Charleston Laboratories Inc.; Dr. Reddy’s Laboratories Ltd; electroCore, LLC; Eli Lilly and Company; eNeura, Inc.; Kimberly-Clark Corporation; PERNIX Therapeutics; Pfizer Inc; ScionNeuroStim; Teva Pharmaceutical Industries Ltd.; Zosano Pharma Corporation

Grant/Research Support:  Alder BioPharmaceuticals Inc.; Allergan Inc.; Amgen Inc; Autonomic Technologies Inc.; Avanir Pharmaceuticals, Inc.; electroCore, LLC; eNeura, Inc.; ScionNeuroStim; Teva Pharmaceutical Industries Ltd.; Zosano Pharma Corporation

Employment Affiliation:  American Headache Society

Royalties/Patents: Springer Publishing Company

Stock Ownership: Autonomic Technologies Inc.

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by independent educational grants from Alder BioPharmaceuticals Inc.; Depomed, Inc.; Supernus Pharmaceuticals, Inc; and Zosano Pharma Corporation.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education; Miller Medical Communications, LLC.; Alder BioPharmaceuticals Inc.; Depomed, Inc.; Supernus Pharmaceuticals, Inc; and Zosano Pharma Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
08/28/2017
Course expires: 
08/27/2018
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
08/28/2017
Course expires: 
08/27/2018
Please login or register to take this course.